Compare
Talphera, Inc. vs Impact Biomedical Inc. vs Jupiter Neurosciences, Inc. vs Lyell Immunopharma, Inc.
| Latest fiscal year | Talphera, Inc. TLPH | Impact Biomedical Inc. IBO | Jupiter Neurosciences, Inc. JUNS | Lyell Immunopharma, Inc. LYEL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $28.0K | $32.0K | $21.8K | $36.0K |
| Revenue growth (YoY) | n/a | n/a | n/a | -41.0% |
| Gross margin | n/a | n/m (computed) | 80.6% | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$14.29M | -$11.84M | -$8.64M | -$274.45M |
| EPS (Diluted) | n/a | -$0.38 | -$0.25 | -$16.06 |
| Operating cash flow | -$11.36M | -$1.89M | -$5.41M | -$150.02M |
| Free cash flow | n/a | n/a | n/a | -$150.80M |
| Cash & equivalents | $5.89M | $3.0K | n/a | $60.18M |
| Total assets | $29.72M | $17.41M | $5.56M | $340.05M |
| Total liabilities | $12.68M | $1.85M | $7.40M | $91.85M |
| Shareholders' equity | $17.04M | $12.61M | -$1.83M | $248.20M |
| Return on year-end equity | -83.9% | -93.9% | n/a | -110.6% |
| Shares outstanding | 49.33M | 104.62M | 34.45M | 21.25M |
Revenue, most recent five fiscal years
| Fiscal year | Talphera, Inc. | Impact Biomedical Inc. | Jupiter Neurosciences, Inc. | Lyell Immunopharma, Inc. |
|---|---|---|---|---|
| Latest | $28.0K Ended 2025-12-31 | $32.0K Ended 2025-12-31 | $21.8K Ended 2025-12-31 | $36.0K Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2024-12-31 | n/a | $0 Ended 2024-12-31 | $61.0K Ended 2024-12-31 |
| 2 years earlier | $651.0K Ended 2023-12-31 | n/a | n/a | $130.0K Ended 2023-12-31 |
| 3 years earlier | $0 Ended 2022-12-31 | $50.0K Ended 2022-12-31 | n/a | $84.68M Ended 2022-12-31 |
| 4 years earlier | $2.82M Ended 2021-12-31 | n/a | n/a | $10.65M Ended 2021-12-31 |